(Q44247201)

1 December 2017

title

Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons (English)

1 reference

1 December 2017

1 reference

Elizabeth J Carey

1

1 reference

1 December 2017

Keith D Lindor

series ordinal

2

1 reference

1 December 2017

publication date

1 September 2012

1 reference

Clinics and research in hepatology and gastroenterology

1 December 2017

published in

1 reference

1 December 2017

volume

36 Suppl 1

1 reference

1 December 2017

page(s)

S61-4

1 reference

Bile acids: short and long term effects in the intestine.

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Biliary lipid composition in idiopathic bile acid malabsorption

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Effect of change of fecal bile acid excretion achieved by operative procedures on 1,2-dimethylhydrazine-induced colon cancer in rats

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N'-nitro-N-nitrosoguanidine in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Effects of N'methyl-N'-nitro-N-nitrosoguanidine and deoxycholic acid on the content of free radicals in rat serum

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

DNA hypomethylation induced by non-genotoxic carcinogens in mouse and rat colon

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Role of bile acids in colorectal carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

In vitro formation of DNA adducts with bile acids

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Bile acids as carcinogens in human gastrointestinal cancers

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Secondary bile acid induced DNA damage in HT29 cells: are free radicals involved?

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Deoxycholate induces mitochondrial oxidative stress and activates NF-kappaB through multiple mechanisms in HCT-116 colon epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Does ursodeoxycholic acid change the proliferation of the colorectal mucosa?. A randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Diagnosis and management of primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970023-2

7 January 2021

10.1016/S2210-7401(12)70023-2

Identifiers

DOI

1 reference

1 December 2017

1 reference